Obesity has been associated with an increased risk of developing acute myeloblastic leukaemia (AML). The outcome of AML patients could thus be dependent on their nutritional status that can be evaluated by the simple measurement of serum albumin (SA) and body mass index (BMI). These two parameters could have a value as prognostic factors to guide patients' management. We evaluated the association between SA levels, BMI, and survival, evaluated as overall survival (OS) and event-free survival. normal weight while 56% were obese/overweight. Serum albumin levels were <30 g/L for 49 patients, and ≥30 g/L for 110. Thirty-four patients with low SA levels were also obese. Favourable OS was associated with SA levels ≥30 g/L (HR = 0.467; 95% CI 0.230-0.946; P = .034) but was not impacted by the BMI. Serum albumin levels appear to be an independent prognostic factor in AML and a better parameter than BMI for evaluating the nutritional status of patients at diagnosis.
In the single-center retrospective study reported here, we investigated how BMI and SA levels, ascertained at the time of diagnosis, could impact OS of adult AML patients. and October 2013 and older than 18 years of age at the time of diagnosis were included. All patients were treated with high-dose cytarabine/aracytine and anthracycline-containing regimens; the calculation of chemotherapy dose was not capped-especially for obese patients. The review board of Nancy University Hospital approved this study. The primary endpoint considered for the study was median overall survival (OS). Secondary endpoints were median event-free survival (EFS), CR rate, and duration of febrile neutropenia.
| Statistical analyses
Patients' characteristics were collected as numbers and percentages and were compared between groups using chi 2 Abbreviations: BMI, body mass index; SD, standard deviation.
censored (excluding dead patients). Event-free survival was measured from the date of diagnosis until the date of AML progression or death from any cause and was censored at final follow-up. Univariate analyses were performed using the log-rank test. Multivariate analyses based on the Cox proportional risk model were performed to determine independent variables associated with OS, including all variables with a P value less than 20% in univariate analysis.
The effect of different covariates was estimated using the hazard ratio and 95% confidence interval (CI). A P value <.05 was considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
3 | RESULTS FIGURE 1 Kaplan-Meier estimation of OS according to serum albumin level at diagnosis At diagnosis, normal weight was observed for 44% (n = 70) of the patients while 56% (n = 89) were obese/overweight. Forty-nine patients (30.8%) had a SA level <30 g/L, and 110 (69.2%) had a SA level ≥30 g/L. When the cohort was divided according to BMI (Table 1) , with a 25 kg/m 2 threshold, no difference was observed in gender distribution (P = .89), median age at diagnosis (P = .05), incidence of secondary disease (P = .65), ELN prognostic groups (P = .46), NPM1 mutational status (P = .66), duration of febrile neutropenia (P = .15), nor first-line treatment response (P = .06). However, duplication of FLT3 (FLT3-ITD) was significantly more frequent in normal-weight patients compared to overweight/obese patients (P = 4.5 × 10
| Patient characteristics

−3
).
When patients were divided into two groups according to their SA level at diagnosis (with a 30 g/L threshold), no difference was observed in gender distribution (P = .27), median age at diagnosis (P = .99), incidence of secondary disease (P = .35), ELN prognostic groups (P = .53), FLT3 status (P = .92), duration of febrile neutropenia (P = .77), nor treatment responses (P = .37). At variance, there was a higher proportion of obese patients in the group with SA levels <30 g/L, in which more patients also had mutated NPM1 (P = .01).
The influence of age was also examined, with a threshold of 60 years old. There was no difference in gender distribution 
| Relationship between BMI, SA levels, and overall survival (OS) in univariate analysis
The median follow-up of the whole cohort was 49 months. Median OS was 23.9 months (95% CI 17.3-39.6). A better OS was statistically significantly associated with a younger age at diagnosis (below 60 years old, P = 2.9 × 10 −3 ), de novo disease (P = 1.2 × 10 Table 2 and Figure 1) . Three-year OS increased at 49% if SA levels ≥30 g/L, versus 29% for patients with hypoalbuminemia (P = .02). In the same way, median EFS was also longer in patients with a SA level ≥30 g/L (20.4 vs 8.61 months; P = 3 × 10
; Figure 2 ). Three-year EFS was 29% in the group with SA ≥30 g/L, versus 13% in the hypoalbuminemia group (P = 3 × 10 −3 ).
| SA is a prognostic factor of OS in multivariate analysis
The hazard ratio for mortality was increased with age at diagnosis >60 years (HR = 2.369, P = .02), unfavourable ELN class (HR = 1.706;
), and FLT3 ITD (HR = 6.325; P < 10
−4
). Interestingly, SA levels retained a prognostic value in multivariate analysis, with a better OS when SA levels are superior to 30 g/L (HR = 0.467; IC95% (0.230-0.946), P = .03; Table 3 ).
FIGURE 2
Kaplan-Meier estimation of event free survival by serum albumin 15 Other patients display a poor outcome and could benefit from full doses calculated on actual BSA.
Other paradoxical observations were made in this study, namely the significantly higher rate of FLT3-ITD in normal-weight patients, which does not however translate with an association between normal BMI and worse outcome. Similarly, NPM1 mutations, considered of good prognosis, 16 were more frequent in patients with low levels of SA who nonetheless fared less well. These data suggest that the nutritional status, assessed through SA levels, might override molecular prognostic factors in newly diagnosed AML.
In conclusion, this report highlights the fact that patients can be simultaneously obese and malnourished 17 and that SA levels seem to be a better parameter than BMI to evaluate patient's nutritional status and prognosis before intensive chemotherapy. The value of this prognostic factor should be assessed in prospective studies since it is easy to measure. Protein/albumin supplementation could therefore be considered before initiating or in the same time starting induction therapy in AML patients with hypoalbuminemia, whatever their BMI. This work was not supported by any grant nor other financial support.
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